Results 41 to 50 of about 10,141,888 (301)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Issues of transition from the pharmaceutical development process to the technology transfer process within the pharmaceutical quality system

open access: yes, 2017
The principles of the pharmaceutical quality system (PQS), which is mandatory for all modern pharmaceu- tical companies, provide for the expansion of the good manufacturing practice (GMP) requirements for the initial stages of the life cycle of medicines:
Asmolova, Natalia; National Pharmaceutical University, Kharkiv, Ukraine   +3 more
core   +1 more source

Basic pharmaceutical technology [PDF]

open access: yes, 2017
The lecture deals with basics of pharmaceutical technology as applied discipline of pharmaceutical science, whose main subject of study is formulation and manufacture of drugs.
Drakalska, Elena, Angelovska, Bistra
core   +2 more sources

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

Impact of DNA-Encoded Chemical Library Technology on Drug Discovery

open access: yesCHIMIA, 2022
DNA-Encoded Chemical Libraries (DELs) have gained momentum over the recent years for the discovery of small-molecule ligands and the technology has been integrated in most of the larger pharmaceutical companies.
Michelle Keller   +2 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

What is the value of logistics for a large pharmaceutical firm? [PDF]

open access: yes, 2007
Thesis (M. Eng. in Logistics)--Massachusetts Institute of Technology, Engineering Systems Division, 2007."June 2007."Includes bibliographical references (leaves 65-69).Understanding business needs arising out of both, external and internal environments ...
Tiwari, Prasoon, M. Eng. Massachusetts Institute of Technology
core  

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

open access: yesMolecular Oncology, EarlyView.
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen   +19 more
wiley   +1 more source

Improving energy efficiency in a pharmaceutical manufacturing environment -- production facility [PDF]

open access: yes, 2009
Thesis (M. Eng.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2009.Cataloged from PDF version of thesis.Includes bibliographical references (p.
Zhang, Endong, M. Eng. Massachusetts Institute of Technology
core  

Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications

open access: yes, 2023
Three-dimensional printing (3DP) is emerging as an innovative manufacturing technology for biomedical and pharmaceutical applications, since the US FDA approval of Spritam as a 3D-printed drug.
Vikas Yadav   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy